Quidel Corp (QDEL) Tops Q3 EPS by 6c, Revenues Beat
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/19/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Wells Fargo Downgrades Netflix (NFLX) to Underweight on Engagement Risks, 'We see tougher choices ahead'
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- SanDisk stock rallies on AI optimism and Fed relief
Quidel Reports Third Quarter 2019 Financial Results
October 30, 2019 4:10 PM EDTSAN DIEGO--(BUSINESS WIRE)-- Quidel Corporation (NASDAQ: QDEL), a provider of rapid diagnostic testing solutions, cellular-based virology assays and molecular diagnostic systems, announced today financial results for the third quarter ended September 30, 2019.
Third Quarter 2019 Highlights
Total revenue increased 8% to $126.5 million, as compared to $117.4 million in the third quarter of 2018. Cardiac Immunoassay revenue increased 2% to $66.8 million, and on a constant currency basis grew 3%. Molecular Diagnostic Solutions revenue was $4.7 million, 5% growth from the third quarter of 2018. Influenza revenue increased 36% to $29.3 million, as... More